Results 81 to 90 of about 28,830 (241)

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant

Pharmaceutics
Background: Levonorgestrel implant is a highly effective hormonal contraceptive, but its efficacy may be compromised when used with cytochrome enzyme inducers such as efavirenz. The primary aim of this study was to evaluate methods of mitigating the drug
Lilian W. Adeojo, Rena C. Patel, Nancy C. Sambol   +2 more
doaj   +1 more source

and Efavirenz‐Containing Antiretroviral Therapy

, 2019
The human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6
Masimirembwa, Collen, Zeruesenay Desta, Jeffrey Lennox, Marelize Swart, Collen Masimirembwa, Lennox, Jeffrey, Aditya H. Gaur, Li Gong, Michelle Whirl‐Carrillo, Chonlaphat Sukasem, Gaur, Aditya H., Jennifer Hockings, Iwuchukwu, Otito F., Klein, Teri E., Sanika Chirwa, Desta, Zeruesenay, Chirwa, Sanika, Haas, David W., David W. Haas, Otito F. Iwuchukwu, Alan Myers, Whirl-Carrillo, Michelle, Rachel F. Tyndale, Hockings, Jennifer, Andrea Gaedigk, Gong, Li, Sukasem, Chonlaphat, Swart, Marelize, Gaedigk, Andrea, Myers, Alan, Tyndale, Rachel F., Roseann S. Gammal, Teri E. Klein, Gammal, Roseann S.   +33 more
core   +1 more source

Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya [PDF]

, 2019
ObjectiveOur objective was to evaluate if increasing body mass index (BMI) or weight influences the association between efavirenz-based antiretroviral therapy (ART) and implant effectiveness.Study designWe conducted a secondary cohort analysis of HIV ...
Patel, Rena C, Wools-Kaloustian, Kara K, Cohen, Craig R, Group, Implant Efavirenz Study, Jakait, Beatrice, Yiannoutsos, Constantin, Bukusi, Elizabeth A, Thomas, Katherine, Onono, Maricianah   +8 more
core   +1 more source

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children.

PLoS ONE, 2019
BackgroundTo access the long term relationship between efavirenz plasma concentrations and evolution of HIV RNA loads and CD4 cell counts in children.MethodsRetrospective analysis of data from HIV-infected children on first line efavirenz-containing ...
Nontiya Homkham, Tim R Cressey, Naim Bouazza, Lily Ingsrisawang, Pornchai Techakunakorn, Jutarat Mekmullica, Thitiporn Borkird, Achara Puangsombat, Sathaporn Na-Rajsima, Jean Marc Treluyer, Saik Urien, Gonzague Jourdain   +11 more
doaj   +1 more source

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS

Pharmaceutical Sciences and Research, 2019
Gangguan metabolik lipid merupakan kondisi yang sering ditemukan pada pasien HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immuno Deficiency Syndrome) pada pasien yang menggunakan antiretroviral (ARV) lini pertama seperti efavirenz dan nevirapine ...
Anggriani Yusi, Evy Yunihastuti, Yulia Trisna, Ade Rosanti, Reise Manninda, Rifka Annisa   +5 more
doaj   +1 more source

Efavirenz concentrations at week 22 and week 50 in patients whose efavirenz concentrations >4,000 ng/mL.

, 2014
Efavirenz concentrations at week 22 and week 50 in patients whose efavirenz concentrations >4,000 ng/mL.
Eric Nerrienet (180004), Chindamony Kim (532515), Anne E. Goldfeld (76177), Didier Laureillard (512339), Olivier Marcy (532512), Narom Prak (532514), Bunnet Dim (532518), Yoann Madec (189155), Monidarin Chou (532511), Phearavin Pheng (532513), Thim Sok (532519), Chanroeun Hak (532517), Arnaud Fontanet (157942), François-Xavier Blanc (532520), Khemarin Kim Lak (532516), Anne-Marie Taburet (288246), Laurence Borand (512340)   +16 more
core   +1 more source

Cholesterol content in IHCs and SCs from control, efavirenz, and efavirenz plus phytosterols-treated mice.

, 2023
(A) Representative confocal images of whole mounts organ of Corti from the medial region stained with filipin in control, treated with efavirenz, and treated with efavirenz plus Phy mice. (Scale bar = 30 μm).
María A. Paulazo (8356731), Alejandro O. Sodero (8356734), María Eugenia Gomez-Casati (16877076), Jimena A. Ballestero (16877070), Mauricio G. Martin (16877073), Setiembre D. Elorza (16877064), Sara M. Gonzalez-Rodulfo (16877067), Valeria C. Castagna (16877061)   +7 more
core   +1 more source

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model [PDF]

, 2022
Ezéchiel Ngoufack Jagni Semengue, Joseph Fokam, Naomi-Karell Etame, Evariste Molimbou, Collins Ambe Chenwi, Désiré Takou, Leonella Mossiang, Alain-Patrice Mélédié, Yagaï Bouba, Alex Durand Nka, Béatrice Dambaya, Georges Této, Aude Christelle Ka’e, Grâce Beloumou, Sandrine Claire Djupsa Ndjeyep, Aissatou Abba, Aurelie Minelle Ngueko Kengni, Michel Carlos Tommo Tchouaket, Nounouce Pamen Bouba, Serge-Clotaire Billong, Samuel Martin Sosso, Vittorio Colizzi, Carlo Federico Perno, Charles Kouanfack, Anne‐Cécile Zoung‐Kanyi Bissek, Emmanuel Eben-Moussi, Maria Mercedes Santoro, Francesca Ceccherini‐Silberstein, Alexis Ndjolo   +28 more
openalex   +1 more source

In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

, 2017
The antiretroviral drug efavirenz displays many desirable pharmacokinetic properties such as a long half-life enabling once daily dosing but suffers from central nervous system safety issues.

core   +1 more source